Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Date
2013
Author
Williams, Michael E.
Drach, Johannes
Ramchandren, Radhakrishnan
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Witzig, Thomas E.
Besisik, Sevgi
Goy, Andre
Sinha, Rajni
Metadata
Show full item record
Abstract
Purpose
URI
http://hdl.handle.net/20.500.12627/104713
https://doi.org/10.1200/jco.2013.49.2835
Collections